Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Induction and Concurrent Chemoradiotherapy for NPC
NCT04522050Phase 1Unknown
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2018
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine in nasopharyngeal carcinoma (NPC), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Maximum Tolerance Dose at 3 years. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04522050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522050.